SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Clemens John)
 

Search: WFRF:(Clemens John) > Development of path...

Development of pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccine against enterotoxigenic Escherichia coli in Egypt: application of an evidence-based method

Clemens, John (author)
Savarino, Stephen (author)
Abu-Elyazeed, Remon (author)
show more...
Safwat, Mohammad (author)
Rao, Malla (author)
Wierzba, Thomas (author)
Svennerholm, Ann-Mari, 1947 (author)
Gothenburg University,Göteborgs universitet,Institutionen för medicinsk mikrobiologi och immunologi,Institute of Medical Microbiology/Immunology
Holmgren, Jan, 1944 (author)
Gothenburg University,Göteborgs universitet,Institutionen för medicinsk mikrobiologi och immunologi,Institute of Medical Microbiology/Immunology
Frenck, Robert (author)
Park, Eunsik (author)
Naficy, Abdollah (author)
show less...
 (creator_code:org_t)
2004
2004
English.
In: J Infect Dis. ; 189:12, s. 2299-307
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • BACKGROUND: To design an efficacy trial of a killed oral vaccine against enterotoxigenic Escherichia coli (ETEC) diarrhea in Egyptian children, we derived for ETEC diarrhea an empirical definition that increased the probability that diarrhea associated with excretion of ETEC was caused by the detected ETEC. METHODS: We conducted a cohort study of 397 Egyptian children <24 months old and monitored them until they were 3 years old. Vaccine-preventable (VP) ETEC was defined as ETEC expressing >/=1 of the toxin- (heat-labile [LT] toxin) and colonization-factor antigens (CFA I, II, and IV) in the vaccine. RESULTS: Although fecal excretion of VP-ETEC was highly associated with diarrhea, excretion of LT-ETEC per se was not related to diarrhea (adjusted odds ratio [OR(A)], 1.16 [95% confidence interval [CI], 0.90-1.49]). The fecal excretion of antigenic types of VP-ETEC other than LT-ETEC (non-LT VP-ETEC) was highly associated with diarrheal symptoms (OR(A), 3.91 [95% CI, 2.78-5.49]; P<.001), and this association was greater for nonbloody than for bloody diarrhea. CONCLUSIONS: Because the vaccine had been anticipated to protect primarily against symptomatic ETEC diarrhea, these results indicate that the primary-outcome definition of ETEC diarrhea for the trial should be restricted to nonbloody diarrheal episodes associated with fecal excretion of non-LT VP-ETEC.

Keyword

Bacterial Toxins/metabolism
Child
Preschool
Clinical Trials/*methods
Diarrhea/microbiology/prevention & control
Egypt
Enterotoxins/metabolism
Escherichia coli/isolation & purification/metabolism/*pathogenicity
Escherichia coli Infections/microbiology/*prevention & control
*Escherichia coli Proteins
Escherichia coli Vaccines/*administration & dosage/therapeutic use
Evidence-Based Medicine
Feces/microbiology
Fimbriae Proteins/metabolism
Humans
Infant
Research Design
Treatment Outcome
Vaccines
Inactivated/*administration & dosage/therapeutic use

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view